Clinical trials: Atopic Dermatitis (Eczema)
Eczema, Dermatitis
Effects of Treatments on Atopic Dermatitis
Background: Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S. aureus bacteria.
- Conditions
- Eczema, Dermatitis, Skin Diseases, Genetic, Dermatitis, Atopic
- Trial name
- NCT01631617
- Testing
- Trimethoprim/sulfamethoxazole (TMP/SMZ), Cephalexin, Doxycycline
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Atopic Dermatitis, Eczema
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis.
- Trial name
- ADorable-2 (NCT05735483)
- Testing
- Lebrikizumab
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 338 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction.
- Trial name
- NCT05995964
- Testing
- PF-07275315, PF-07264660
- Where
- 96 sites in United States, Australia and 5 more
- Volunteers
- 507 people
- Sponsor
- Pfizer
Atopic Dermatitis (AD), Eczema
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)…
- Trial name
- NCT07453602
- Testing
- ARQ-234
- Where
- 7 sites in United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Arcutis Biotherapeutics, Inc.
Atopic Dermatitis, Eczema
Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis
Atopic dermatitis is well reported to have a significant impact on well-being in adolescents with atopic dermatitis, without clear recommendations for intervention.
- Trial name
- MIND-AD (NCT07746427)
- Testing
- Digital App Mindfulness Meditation, Mindfulness Meditation Sheet
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Weill Medical College of Cornell University
Atopic Dermatitis, Atopic Hand Eczema
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
The purpose of this study is to test if treatment with tralokinumab is safe and efficacious in treating moderate-to-severe atopic hand eczema.
- Trial name
- ADHAND (NCT05958407)
- Testing
- Tralokinumab
- Where
- 69 sites in United States, Belgium and 8 more
- Volunteers
- 235 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema).
- Trial name
- Tilrek (NCT07783425)
- Testing
- Tilrekimig, Dupilumab
- Where
- 32 sites in United States, Japan
- Volunteers
- 1,375 people
- Sponsor
- Pfizer
Atopic Dermatitis
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device.
- Trial name
- Detect-AD (NCT07645820)
- Testing
- Nevisense electrical impedance spectroscopy
- Where
- 13 sites in United States
- Volunteers
- 450 people
- Sponsor
- Castle Biosciences Incorporated
Eczema
Educational Eczema Video Intervention
The objectives of this study are to increase families' understanding of eczema and improve eczema management in the primary care setting.
- Trial name
- NCT03664271
- Testing
- in-clinic video intervention, at home video intervention
- Volunteers
- healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Atopic Dermatitis, Eczema
Efficacy Evaluation and Cutaneous Acceptibility of a Dermocosmetic Product on Subjects Suffering of Atopic Dermatisis.
Atopic eczema is a chronic inflammatory skin disease, mainly affecting children, characterized by itching and flare-ups. It results from genetic and environmental factors, leading to immunological and cutaneous abnormalities.
- Trial name
- NCT06756438
- Testing
- Study product
- Where
- Poland
- Volunteers
- 88 people
- Sponsor
- NAOS Les Laboratoires
Atopic Dermatitis
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and…
- Trial name
- TRuE-AD4 (NCT06238817)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 94 sites in United States, Australia and 12 more
- Volunteers
- 241 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic…
- Trial name
- NCT07765888
- Testing
- Tilrekimig
- Where
- 21 sites in United States, Japan
- Volunteers
- 375 people
- Sponsor
- Pfizer
Eczema, Atopic Dermatitis
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease.
- Trial name
- NCT00605878
- Where
- United States
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Atopic Dermatitis
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06807281
- Testing
- Abrocitinib
- Where
- 39 sites in United States, China and 5 more
- Volunteers
- 450 people
- Sponsor
- Pfizer
Atopic Dermatitis, Eczema
Clinical-Instrumental Study To Evaluate And Compare The Efficacy And Tolerability Of Two Emollients Products In Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with erythema, scaly and oozing plaques, and severe pruritus which has an important impact on quality of life and quality of sleep.
- Trial name
- NCT06930365
- Testing
- Anti-itching and repairing treatment. Emollient., Emollient cream
- Where
- Georgia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- NAOS Les Laboratoires
Atopic Dermatitis, Eczema, Atopic
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema.
- Trial name
- NCT07216027
- Testing
- PF-08049820
- Where
- 42 sites in United States, Bulgaria and 6 more
- Volunteers
- 165 people
- Sponsor
- Pfizer
Dermatitis, Atopic
Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
A long-term observational registry in patients with atopic dermatitis (AD) initiating treatment with DUPIXENT® (dupilumab)
- Trial name
- PROSE (NCT03428646)
- Testing
- Dupilumab
- Where
- 99 sites in United States, Canada
- Volunteers
- 858 people
- Sponsor
- Regeneron Pharmaceuticals
Healthy Volunteer, Atopic Dermatitis
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
This study will test a study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B).
- Trial name
- AURA-AD (NCT07527923)
- Testing
- REGN20423
- Where
- 7 sites in United States, Belgium
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis (AD)
The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.
- Trial name
- AD (NCT06928246)
- Testing
- Onabotulinum Toxin Type A - Phase 1b, Onabotulinum Toxin Type A - Phase 2
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Daniel Kaplan
Atopic Dermatitis
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT07150845
- Testing
- EVO756
- Where
- 29 sites in United States, New Zealand
- Volunteers
- 121 people
- Sponsor
- Evommune, Inc.